Sharon Mates, Ph.D.
Sharon Mates received her Ph.D. in Neuroanatomy and Neuroscience from the University of Washington in 1981. Following postgraduate work at Harvard Medical School and the Massachusetts General Hospital, Dr. Mates established and managed a small business, followed by a position as a research analyst and investment banker in San Francisco. From 1989-1998 Dr. Mates was the President of North American Vaccine and its predecessor companies. Dr. Mates was a co-founder of Functional Genetics Inc. and served as its Chairman and CEO from December 2000-August 2003. Upon co-founding ITI and through August 2003, Dr. Mates was the CEO of FGI and ITI. In August 2003, Dr. Mates relinquished her leadership role in FGI to accelerate the growth of ITI. She is an emeritus member of the Board of Visitors of the Biotechnology Institute of the University of Maryland, a member of the Advisory Council of the Center for Society and Health at the Harvard School of Public Health and a board member of Gilda's Club New York and The New York Biotechnology Association.
Allen A. Fienberg, Ph.D.
Dr. Fienberg received his Ph.D. in Human Genetics from Yale University in 1991. As a post-doctoral fellow in the laboratory of Paul Greengard at the Rockefeller University, he created the knockout mouse for DARPP-32 and led an effort of over 20 laboratories worldwide to analyze the phenotype. In 1999, Dr. Fienberg was appointed a staff scientist at the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego and an Adjunct Professor of Neuropharmacology at The Scripps Research Institute. At GNF he led a collaborative initiative (with industry and academia) to exploit the advanced technique of gene chip analysis to search for new therapeutic targets relevant to schizophrenia, Parkinson's disease, stroke and drug addiction and is an author on more than fifty publications. Dr. Fienberg brings to the position of Vice President of Business Development an expert understanding of the science upon which ITI is based, a knowledge of how to exploit the intellectual property landscape to build ITI and a proven ability to set up the various types of collaborations necessary to build and sustain the business.
Lawrence P. Wennogle, Ph.D.
Dr. Wennogle received his Ph.D. in Biochemistry from the University of Colorado, Boulder in 1977. For more than twenty two years, Dr. Wennogle held positions at Novartis and Ciba-Geigy, where he participated in and led drug discovery programs for CNS disorders, cardiovascular disease, diabetes and inflammation. With his broad expertise in drug discovery and the biochemical basis of disease, Dr. Wennogle serves as the company’s Vice President of Drug Discovery.
From 1993 - 2000, Mr. Hineline served North American Vaccine and its predecessor companies as Vice President of Finance, and from 1989 - 1993 as its Corporate Controller. During this time, Mr Hineline oversaw the growth of the Accounting function and its systems for this company that emerged as a start-up and was later acquired by Baxter Health Care. Prior to 1989, he held the position of Controller for several businesses and from 1981- 1984, he worked in the Audit Department of Deloitte & Touche serving clients in a variety of industries. Mr. Hineline is a licensed CPA in the State of Maryland.
Dr. Kimberly Vanover has spent over 15 years on the discovery and development of small molecule drugs for the treatment of neuropsychiatric and neurodegenerative diseases. After completing her Ph.D. in the field of Biopsychology from the University of Chicago, Dr. Vanover held positions at Lederle Laboratories, the University of California San Diego, CoCensys and ACADIA Pharmaceuticals. In these positions, she participated in the discovery and development of a broad range of new CNS therapeutics, including drugs to treat psychosis, insomnia, cognitive impairment, movement disorders, acute and neuropathic pain, anxiety, epilepsy, and drug abuse. Dr. Vanover joined ITI in 2007 and now serves as the Vice President of Clinical Development.